The tPA/PAI-1 ratio, reflecting the net fibrinolytic activity of serum, was reduced in the post-COVID-19 group as compared to the control serum: 1.3 ± 0.1 vs. 1.6 ± 0.1 (p < 0.001). The gene discussed is PLAT; the disease is COVID-19.